VBS Pharmaceuticals

VBS Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for difficult-to-treat vascular diseases and inflammatory conditions. The company's lead candidate, VBS-1, is a first-in-class therapy for Pulmonary Arterial Hypertension (PAH) designed to reverse pulmonary vascular remodeling by activating the PPAR-gamma pathway. VBS also utilizes its proprietary CAR peptide technology, a cyclic peptide that selectively homes to diseased or injured tissues, to enhance the delivery of various therapeutic agents. Their pipeline addresses critical unmet needs in respiratory medicine, oncology, and critical care, including treatments for ARDS and sepsis. The company operates as the pharmaceutical development arm of Vascular BioSciences.